Jubilant Life Sciences
Jubilant Life Sciences, a prominent player in the pharmaceutical and life sciences sector, is headquartered in Noida, India. Founded in 1978, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in contract manufacturing, active pharmaceutical ingredients (APIs), and drug delivery solutions, Jubilant Life Sciences is recognised for its commitment to quality and innovation. The company’s core offerings, which include a diverse range of generic pharmaceuticals and specialty chemicals, set it apart in a competitive market. With a focus on sustainability and advanced technology, Jubilant Life Sciences has achieved significant milestones, including multiple regulatory approvals and partnerships with leading global firms. This positions the company as a trusted partner in the healthcare industry, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does Jubilant Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jubilant Life Sciences's score of 46 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jubilant Life Sciences's reported carbon emissions
In 2024, Jubilant Life Sciences reported total carbon emissions of approximately 8620000 kg CO2e for Scope 1, 68152000 kg CO2e for Scope 2, and 737234000 kg CO2e for Scope 3, resulting in a combined total of about 76772000 kg CO2e for Scope 1 and 2. This reflects a significant commitment to transparency in their emissions reporting across all scopes. The company has set ambitious climate commitments, aiming for net zero emissions by 2050. This long-term target encompasses both Scope 1 and Scope 2 emissions, with initiatives already underway to improve processes that lead to energy conservation and reduced emissions. Specifically, from 2023 to 2025, Jubilant Life Sciences is focusing on enhancing operational efficiencies to lower emissions in the near term. In 2023, emissions were recorded at approximately 8492000 kg CO2e for Scope 1, 54703000 kg CO2e for Scope 2, and 662296000 kg CO2e for Scope 3, indicating a proactive approach to managing their carbon footprint. The company continues to disclose emissions data, demonstrating a commitment to sustainability and accountability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jubilant Life Sciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
